Corvus Pharmaceuticals (CRVS) Enterprise Value (2015 - 2026)

Corvus Pharmaceuticals' Enterprise Value history runs 12 years deep, the most recent figure standing at -$236.7 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 4635.23% year-over-year to -$236.7 million; the TTM figure through Mar 2026 stood at -$236.7 million (down 4635.23% YoY), while the FY2025 annual figure was -$56.8 million, down 9.21% from the prior year.
• Enterprise Value was -$236.7 million for Q1 2026 at Corvus Pharmaceuticals, down from -$56.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$2.9 million in Q3 2025 to a low of -$236.7 million in Q1 2026.
• Historically, Enterprise Value has averaged -$31.9 million across 5 years, with a median of -$14.7 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Enterprise Value soared 79.26% in 2022, then slumped 4635.23% in 2026.
• A 5-year view of Enterprise Value shows it stood at -$13.2 million in 2022, then climbed by 4.1% to -$12.6 million in 2023, then tumbled by 311.76% to -$52.0 million in 2024, then slipped by 9.21% to -$56.8 million in 2025, then sank by 317.12% to -$236.7 million in 2026.
• The last three Enterprise Value figures came in at -$236.7 million (Q1 2026), -$56.8 million (Q4 2025), and -$2.9 million (Q3 2025), per Business Quant data.